MX2011009757A - Metodo para tratar esteatohepatitis no alcoholica con elevadas dosis de acido ursodeoxicolico. - Google Patents

Metodo para tratar esteatohepatitis no alcoholica con elevadas dosis de acido ursodeoxicolico.

Info

Publication number
MX2011009757A
MX2011009757A MX2011009757A MX2011009757A MX2011009757A MX 2011009757 A MX2011009757 A MX 2011009757A MX 2011009757 A MX2011009757 A MX 2011009757A MX 2011009757 A MX2011009757 A MX 2011009757A MX 2011009757 A MX2011009757 A MX 2011009757A
Authority
MX
Mexico
Prior art keywords
ursodeoxycholic acid
nonalcoholic steatohepatitis
treating nonalcoholic
elevated doses
treatment
Prior art date
Application number
MX2011009757A
Other languages
English (en)
Inventor
Jean Spenard
Vlad Ratziu
Marc Riviere
Original Assignee
Axcan Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcan Pharma Inc filed Critical Axcan Pharma Inc
Publication of MX2011009757A publication Critical patent/MX2011009757A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se dirige a un método para el tratamiento de esteatohepatitis no alcohólica (NASH) mediante la administración de una dosis elevada de ácido ursodeoxicólico (UDCA) o una sal farmacéuticamente aceptable del mismo, a un paciente que necesita tal tratamiento, en donde los pacientes demuestran un perfil glucémico significativamente mejorado durante el tratamiento.
MX2011009757A 2009-03-17 2010-03-16 Metodo para tratar esteatohepatitis no alcoholica con elevadas dosis de acido ursodeoxicolico. MX2011009757A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16095509P 2009-03-17 2009-03-17
PCT/IB2010/000551 WO2010106420A1 (en) 2009-03-17 2010-03-16 Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid

Publications (1)

Publication Number Publication Date
MX2011009757A true MX2011009757A (es) 2012-02-28

Family

ID=42167374

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009757A MX2011009757A (es) 2009-03-17 2010-03-16 Metodo para tratar esteatohepatitis no alcoholica con elevadas dosis de acido ursodeoxicolico.

Country Status (12)

Country Link
US (1) US20120071451A1 (es)
EP (1) EP2408457A1 (es)
JP (1) JP2012520866A (es)
KR (1) KR20120008034A (es)
CN (1) CN102361642A (es)
AU (1) AU2010224587A1 (es)
CA (1) CA2755708A1 (es)
IL (1) IL215195A0 (es)
MX (1) MX2011009757A (es)
RU (1) RU2011139643A (es)
WO (1) WO2010106420A1 (es)
ZA (1) ZA201107578B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
KR101401628B1 (ko) * 2012-12-24 2014-06-02 삼성제약공업주식회사 간기능 개선용 정제 및 그 제조 방법
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
CA2949834A1 (en) 2014-05-28 2015-12-03 James Macormack Wells Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10301303B2 (en) * 2014-07-29 2019-05-28 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
WO2016061464A1 (en) 2014-10-17 2016-04-21 Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intetine using pluripotent stem cells and methods of making and using same
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
CN116440143A (zh) * 2015-11-19 2023-07-18 欣耀生医股份有限公司 预防或治疗脂肪肝的药物组合物
EP3452578B1 (en) 2016-05-05 2022-08-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
US20200056157A1 (en) 2016-11-04 2020-02-20 Children's Hospital Medical Center Liver organoid disease models and methods of making and using same
AU2017373767B2 (en) 2016-12-05 2021-09-16 Children's Hospital Medical Center Colonic organoids and methods of making and using same
JP2020524684A (ja) * 2017-06-21 2020-08-20 ノバルティス アーゲー 非アルコール性脂肪性肝炎の治療のためのリコフリゴジン
KR101887561B1 (ko) * 2017-11-15 2018-09-06 주식회사 대웅제약 간염 바이러스에 의해 유발된 간 섬유화의 개선을 위한 약학 조성물
RU2686042C1 (ru) * 2018-09-04 2019-04-23 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ лечения неалкогольной жировой болезни печени при метаболическом синдроме
CA3148431A1 (en) * 2019-07-30 2021-02-04 Kobiolabs, Inc. Kit for predicting or diagnosing nonalcoholic fatty liver disease, and method for diagnosing nonalcoholic fatty liver disease
CN114207143A (zh) * 2019-07-30 2022-03-18 Ko生物技术有限公司 预测或诊断非酒精性脂肪肝病的试剂盒及诊断非酒精性脂肪肝病的方法
CN115137732A (zh) * 2021-03-29 2022-10-04 中国科学院大连化学物理研究所 Gpr120受体激动剂及熊去氧胆酸的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297229B1 (en) * 1994-11-14 2001-10-02 Mayo Foundation For Medical Education And Research Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis

Also Published As

Publication number Publication date
IL215195A0 (en) 2011-12-29
JP2012520866A (ja) 2012-09-10
AU2010224587A1 (en) 2011-09-22
KR20120008034A (ko) 2012-01-25
WO2010106420A1 (en) 2010-09-23
ZA201107578B (en) 2013-06-26
US20120071451A1 (en) 2012-03-22
CN102361642A (zh) 2012-02-22
CA2755708A1 (en) 2010-09-23
EP2408457A1 (en) 2012-01-25
RU2011139643A (ru) 2013-04-27

Similar Documents

Publication Publication Date Title
MX2011009757A (es) Metodo para tratar esteatohepatitis no alcoholica con elevadas dosis de acido ursodeoxicolico.
MX362626B (es) Métodos para tratar pacientes pediátricos usando dexmedetomidina..
MX2016005532A (es) Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades.
MX2012007875A (es) Uso de derivados de 5-[[2, 3-dimetil-2h-indazol-6-il)-metilamino]- 2-pirimidil] amino]-2-metilbencensulfonamida en transtornos oculares.
IN2012DN03172A (es)
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2013003060A (es) Terapia de combinacion para tratar infeccion por hcv.
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
EP2418956A4 (en) METHOD FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA
MX357556B (es) Composiciones acuosas que comprenden arbekacina.
MX2012013374A (es) Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos.
RU2013104381A (ru) Лечение отслойки васкуляризированного пигментного эпителия терапевтическим средством против vegf
WO2011133826A3 (en) Method for treating pancreatic cancer
WO2011056850A3 (en) Linaclotide for the treatment of chronic constipation
WO2011072181A3 (en) Method of treating pancreatic cancer
WO2012116357A3 (en) Use of agr3 for treating cancer
BR112012011316A2 (pt) tivozanib e temsirolimus em combinação
WO2011133827A3 (en) Method of treating prostate cancer
WO2012075210A3 (en) Method for treating refractory cancer
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
WO2012012304A3 (en) Method of treating refractory cancer
WO2011139867A3 (en) Method of treating brain cancer
UA59667U (ru) Способ медицинской реабилитации больных неалкогольным стеатогепатитом с использованием средств антигомотоксической терапии
UA69684U (ru) Способ медицинской реабилитации больных неалкогольным стеатогепатитом, соединенным с дисбиозом кишечника
UA65525U (ru) Способ лечения больных ишемической болезнью сердца

Legal Events

Date Code Title Description
FA Abandonment or withdrawal